Abstract Type 2 diabetes mellitus (T2DM) accounts for more than 90% of all cases of diabetes mellitus (DM). Diabetic neuropathic pain (DNP) is a common complication of T2DM. Sinomenine is a natural bioactive component extracted from the Sinomenium acutum and has antiinflammatory effects. The aim of our study was to investigate the effects of sinomenine on DNP mediated by the P2X 3 receptor in dorsal root ganglia (DRG). The mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) in T2DM rats were lower than those of control rats. MWT and TWL in T2DM rats treated with sinomenine were higher compared with those in T2DM rats. The expression levels of the P2X 3 protein and mRNA in T2DM rat DRG were higher compared with those of the control, while those in T2DM rats treated with sinomenine were significantly lower compared with those of the T2DM rats. Sinomenine significantly inhibited P2X 3 agonist ATP-activated currents in HEK293 cells transfected with the P2X 3 receptor. Sinomenine decreased the phosphorylation and activation of P38MAPK in T2DM DRG. Therefore, sinomenine treatment may suppress the up-regulated expression and activation of the P2X 3 receptor and relieve the hyperalgesia potentiated by the activation of P38MAPK in T2DM rats.
Introduction
Chronic neuropathic pain is a major public health problem, greatly impairs quality of life, and has a high economic impact on society [1] . The mechanism of chronic neuropathic pain is extremely complex, and it is very difficult to treat [2, 3] . Type 2 diabetes mellitus (T2DM) accounts for more than 90% of all cases of diabetes and is a complex heterogeneous disease [4] [5] [6] [7] . Diabetic peripheral neuropathy (DPN) is a very common complication of T2DM. DPN is a frequent complication of T2DM and a major cause of morbidity and increased mortality [8, 9] . DNP is characterized by spontaneous pain, allodynia (pain to normally innocuous stimuli), and hyperalgesia (increased pain perception to noxious stimuli) [5, 6, [10] [11] [12] . Diabetic neuropathic pain treatment is difficult because no specific relief medication is available [6, 10, 12] . Although numerous studies have examined the mechanisms underlying hyperglycemia-induced nerve damage, the exact mechanism by which T2DM causes neuropathy has not been clearly elucidated.
Adenosine-5′-triphosphate (ATP), a non-selective agonist for each of the ionotropic P2X receptors, is involved in the transmission of painful sensory information from the periphery to the CNS [13] [14] [15] . The P2X 3 receptor is a trimeric cation channel gated by extracellular ATP and most highly expressed in small diameter neurons of the DRG [13] [14] [15] . The P2X 3 receptor is an important transducer of nociceptive stimuli and altered P2X 3 receptor after nerve injury contributes to neuropathic pain hypersensitivity [16] [17] [18] [19] . Expression levels of the P2X 3 receptor in the DRG are increased in chronic constriction injury (CCI) rat models [13] [14] [15] [16] [17] . The P2X 3 receptor is up-regulated during diabetic neuropathy and changes in the expression of P2X 3 , correlating with the development of hyperalgesia [20] [21] [22] [23] .
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Sinomenine is a natural bioactive component extracted from the climbing plant Sinomenium acutum [24] [25] [26] [27] [28] . Sinomenine reduces joint swelling, erythrocyte sedimentation rate, production of antibodies, and secretion of cytokines in animal models of arthritis [24, 26] . It was reported that sinomenine attenuated neuropathic pain hypersensitivity [24] [25] [26] [27] [28] . However, its exact mechanism of action is not clearly understood. Sinomenine also alleviates high glucose-induced diabetic complications [29, 30] . Our studies showed that the effects of sinomenine on hyperalgesia correlate with modulating the expression of the P2X 3 receptor in DRG in a T2DM rat model. Thus, the P2X 3 receptor may be a target for the analgesic properties of sinomenine. The aim of this study was to investigate the effects of sinomenine on the P2X 3 receptor in DRG-mediated DNP.
Materials and methods

Animals groups
Male Sprague-Dawley (SD) rats (180-230 g) were provided by the Center of Laboratory Animal Science of Nanchang University. The procedures were approved by the Animal Care and Use Committees of Nanchang University Medical Schools. The animals were housed in plastic boxes in groups of three at 21-25°C. The IASP's ethical guidelines for pain research in animals were followed. All animals were treated according to the ARVO Statement for the use of Animals in Ophthalmic and Vision Research in China. Type 2 diabetic model rats were given a high-fat diet (consisting of 22% fat, 48% carbohydrate, and 20% protein with a total calorific value of 44.3 kJ/kg) for 4 weeks and were subsequently injected intraperitoneally (i.p.) with a low dose of streptozotocin (STZ; 30 mg/kg) [31] [32] [33] . After 1 week of STZ injection, rats with a fasting blood glucose >7.8 mmol/L or non-fasting blood glucose >11.1 mmol/L were considered to be type 2 diabetic model rats. Control rats were fed regular chow (consisting of 5% fat, 53% carbohydrate, 23% protein, with a total calorific value of 25 kJ/kg) and were treated with vehicle citrate buffer (pH 4.4) in a volume of 0.25 mL/kg (i.p.) [31] [32] [33] .
Rats were assigned in a random blind manner to one of three groups: the control group (control group), the diabetic model group (DM group), and DM rats treated with the sinomenine group (DM + sinomenine group); each group contained ten animals. The DM + sinomenine group consisted of diabetic animals treated with sinomenine (40 mg kg −1 day −1 , i.p.) on the 1st through the 14th day after the DM rats were identified. Sinomenine (standard substance) was purchased from the National Institute for Food and Drug Control (Beijing, China), and the purity is 99%.
Thermal hyperalgesia
The latency to hind paw withdrawal from a thermal stimulus was determined by exposing the plantar surface of the hind paw to radiant heat using the Thermal Paw Stimulation System (BME-410C, Tianjin) [21, 22, 31] . Rats were placed in a transparent, square, bottomless acrylic box (22 × 12 × 22 cm) on a glass plate under which a light was located. After a 30-min habituation period, the plantar surface of the paw was exposed to a beam of radiant heat applied through the glass floor. Activation of the bulb simultaneously activated a timer, and both were immediately turned off by paw withdrawal or at the 25-s cutoff time. The hind paws were tested by a blinded observer in triplicate at 5-min intervals.
Mechanical hyperalgesia
The mechanical nociceptive threshold was evaluated by observing withdrawal responses to mechanical stimulation using von Frey filaments (Stoelting, Wood Dale, IL, USA) [21, 22, 31] . A linearly increasing pressure by a von Frey filament was applied, starting with 0.13 g and continuing until a withdrawal response occurred or the force reached 20.1 g (the cutoff value). The pressure was applied through a cone-shaped plastic tip with a diameter of 1 mm onto the dorsal surface of the hind paws. The tip was positioned between the third and fourth metatarsus, and the force was applied until the rat attempted to withdraw its paw (paw withdrawal threshold to pressure). The hind paws were tested alternately at 2-min intervals. The pain threshold was determined by a blinded observer as the mean of three consecutive stable values and expressed in grams.
Western blotting
Animals were anesthetized with penthiobarbital sodium, and the DRG were dissected. Approximately six to ten samples were harvested from each rat. The DRG were isolated immediately and rinsed in ice-cold PBS [21, 22] . After dilution with sample buffer (250 mmol/L Tris-Cl, 200 mmol/L dithiothreitol, 10% sodium dodecyl sulfate (SDS), 0.5% bromophenol blue, and 50% glycerol) and heating to 95°C for 10 min, 20-μg samples of total protein (for P2X 3 receptor analysis) were separated using 10% SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. After incubation with the primary antibody against the P2X 3 receptor (CHEMICON International, Inc. USA), the membrane was incubated with peroxidaseconjugated secondary antibodies (Cell Signaling Technology, Danvers, MA, USA). Immunodetection was performed using the Pierce-enhanced chemiluminescence substrate (Thermo Scientific, Waltham, MA, USA). The β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as a loading control. The following were the primary antibodies and dilutions used: rabbit polyclonal anti-P2X 3 (1:1000; Chemicon International Company of America), m o n o c l o n a l β -a c t i n ( 1 : 1 0 , 0 0 0 ; A d v a n c e d Immunochemicals, Long Beach, CA), rabbit anti-p-P38MAPK antibody (1:1000 dilutions; Cell Signaling Technology, Beverly, MA, USA), and rabbit anti-P38MAPK antibody (1:1000; Cell Signaling Technology, Beverly, MA, USA). Band intensity was quantified using Image Pro-Plus software. The relative band intensity of target proteins was normalized against the intensity of respective β-actin bands as internal controls.
Real-time RT-PCR
Total RNA was isolated from DRG using the Trizol Total RNA Reagent. Complementary DNA (cDNA) synthesis was performed with 2 μg of total RNA using the RevertAid™ H Minus First Strand cDNA Synthesis Kit. The primers were designed with Primer Express 3.0 software (Applied Biosystems), and the sequences were as follows: P2X 3 , forward: 5′-ACAGAGTCATGGACGTGTCG-3′, and reverse: 5′-TGAGGTTAGGCAGGAGG TTT-3′; β-actin, forward: 5′-TAAAGACCTCTATGCCAACACAGT-3′, and reverse: 5′-CACGATGGAGGGGCCGGACTCATC-3′. quantitative PCR was performed using the SYBR® Green MasterMix in an ABI PRISM® 7500 Sequence Detection System (Applied Biosystems Inc., Foster City, CA). The quantification of gene expression was performed using the ΔΔCT calculation with CT as the threshold cycle. The relative levels of target genes, normalized to the sample with the lowest CT, were given as 2 −ΔΔ CT [7, 22] .
HEK293 cell culture and transfection
HEK 293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were transiently transfected with the human pcDNA3.0-EGFP-P2X 3 plasmid using Lipofectamine 2000 reagent (Invitrogen) according to the m a n u f a c t u r e r 's i n s t r u c t i o n s [ 3 4 , 3 5 ] . W h e n HEK293 cells were 70-80% confluent, cell culture media was replaced with Opti-MEM 2 h before transfection. The transfection media were prepared as follows: (a) 4 μg of plasmid DNA was diluted to a final volume of 250 μl with Opti-MEM; (b) 10 μl of Lipofectamine 2000 was diluted into 250 μ l final volume of Opti-MEM; and (c) the Lipofectamine-containing solution was mixed with the plasmid-containing solutions and incubated at RT for 20 min. Subsequently, 500 μl of cDNA/Lipofectamine solution was added to each well. The cells were incubated for 6 h at 37°C, 5% CO 2 . After incubation, the cells were washed in Opti-MEM containing 10% FBS and incubated for 24-48 h. The GFP fluorescence was assessed as a reporter for the efficiency of transfection. Whole cell patch clamp recordings were carried out 1-2 days after transfection.
Electrophysiological recordings
Electrophysiological recording was carried out using a patch/ whole cell clamp amplifier (Axopatch 200B) [34, 35] . Single HEK293 cells that expressed green fluorescence implied P2X 3 receptor expression. HEK293 cells expressing green fluorescence were subjected to electrophysiological recording [34, 35] . Microelectrodes were filled with internal solution composed of (mM) 145 K gluconate, 0.75 EGTA, 10 HEPES, 0.1 CaCl 2 , 2 MgATP, and 0.3 Na 3 GTP. The bath was continuously perfused with extracellular solution containing (mM) 126 NaCl, 2.5 KCl, 10 glucose, 1.2 MgCl 2 , 2.4 CaCl 2 , and 18 NaHCO 3 . The osmolarity of the extracellular and internal solutions was adjusted to 340 mOsm with sucrose, and the pH in the extracellular solution was adjusted to 7.4 with NaOH while that of the internal solution was adjusted to 7.3 with KOH for HEK293 cells. The resistance of recording electrodes was 2-6 MΩ. A small patch of membrane underneath the tip of the pipette was aspirated to form a seal (1-10 GΩ), and then more negative pressure was applied to rupture it. The holding potential (HP) was set at −70 mV. ATP (Sigma), sinomenine, and A317491 (Sigma) were dissolved in the external solution. Drugs were applied rapidly through a manifold comprising ten capillaries made of fused silica coated with polyimide with a 200-μm internal diameter. The distance from the tubule mouth to the cell examined was approximately 100 μm. Solutions were delivered by gravity flow from independent reservoirs. One barrel was used to apply drug-free external solution to enable rapid termination of drug application. Drugs were separately applied for 2 s at 4-min intervals, a time which was sufficient for responses to be reproducible. Data were low-pass filtered at 2 Hz, digitized at 5 kHz, and stored on a laboratory computer using a Digidata 1200 interface and pClamp10.0 software (Axon instruments). Concentration-response curves were performed by Sigmaplot12.0 software. Traces were acquired using pClamp software and plotted using Origin 8 (Microcal, Northampton, MA, USA).
Molecular docking
Molecular docking computations were performed using AutoDock 4.2 [36, 37] . Molecular docking is a computer simulation tool that attempts to predict the binding mode of a ligand in the active site of a protein. Molecular docking studies mimic the natural interaction of a ligand with the protein. The technique of docking is to position the ligand in different orientations and conformations within the binding site to calculate optimal binding geometries and energies. Therefore, after the docking procedure, the proper conformation of ligand in the active site of protein is obtained and used for calculation of molecular descriptors. For each ligand, a number of configurations called poses are generated and scored [37] . The score can be calculated as either a free energy of binding, which takes into account salvation and entropy, or the enthalpic term of the free energy of binding, or a qualitative shaped-based numerical measure. The final topscoring poses, along with their scores and conformation energies, are written to a database where they are ready for further analysis.
Protein Data Bank entry 5SVK, which is a crystal structure of the open-state ATP-gated human P2X 3 ion channel in the ATP bound [38] , was used as a target protein [39] . Sinomenine and pubchem CID 5459308 were used as ligands. Both of them were prepared with AutoDockTools (ADT) [36] and Python scripts named prepare_ligand4.py and prepare_receptor4.py, which are associated with the AutoDock4.2 program. The binding pocket position in target protein was specified with the ADT molecular viewer. The parameters were kept at their default values. Finally, the output files were viewed using MGLtools [36] and PyMol (http://www.pymol.org/).
Statistical analysis
Statistical analyses of the data were performed on a computer (SPSS 11.5). All of the results were expressed as the mean ± SE. Statistical significance was determined using one factor analysis of variance (ANOVA) followed by the Fisher post hoc test for multiple comparisons. p < 0.05 was considered significant.
Results
Effects of sinomenine on mechanical or thermal hyperalgesia in T2DM rats
The mechanical withdrawal threshold (MWT) was measured. The MWT in the DM group was lower than the control group (p < 0.05). The MWT in T2DM rats treated with sinomenine was enhanced by about 50% compared with that of T2DM rats (p < 0.01) (Fig. 1a) . These results showed that sinomenine inhibited pain behaviors by increasing the mechanical hyperalgesia threshold in DM rats.
The thermal withdrawal latency (TWL) in the T2DM group was lower compared with that in the control group (p < 0.05). The TWL in T2DM rats treated with sinomenine was increased by about 80% compared with that in the T2DM rats (p < 0.01) (Fig. 1b) . These results revealed that sinomenine treatment also elevated the thermal hyperalgesia threshold in T2DM rats, suggesting that sinomenine treatment may relieve diabetic neuropathic pain.
Effects of sinomenine on the expression levels of DRG P2X 3 mRNA, and protein in T2DM rats
The expression of DRG P2X 3 messenger RNA (mRNA) was examined in each group using real-time RT-PCR. The expression of P2X 3 mRNA in the DM group were higher compared with that in the control group (p < 0.01, n = 10 for each group).
The expression values of P2X 3 mRNA in the T2DM rats treated with sinomenine were decreased by about 28% compared with those of rats in the DM group (p < 0.01, n = 8 for each group) (Fig. 2a) . These results indicated that sinomenine treatment may cut down the up-regulated expression of DRG P2X 3 mRNA in T2DM rats.
The expression of P2X 3 protein in DRG was further studied by western blotting analyses. The expression of P2X 3 protein (normalized against the β-actin internal control) in the DM group was higher compared with the control group (p < 0.01, n = 10 for each group). The expression of P2X 3 protein in the T2DM rats treated with sinomenine was reduced by 35% compared with that in the DM group (p < 0.01, n = 8 Fig. 1 Effects of sinomenine on the mechanical withdrawal threshold and thermal withdrawal latency in T2DM rats. a The mechanical withdrawal threshold (MWT) was measured. The MWT in T2DM rats treated with sinomenine was higher than that of the T2DM rats (p < 0.01). The upper limit of MWT detection was 26.0 g. Mean ± SEM, n = 10. **p < 0.01 compared with the control group; ## p < 0.01 compared with the DM group. b The thermal withdrawal latency (TWL) was measured. The TWL in DM rats treated with sinomenine was higher than that of the DM rats (p < 0.01). The upper limit of the thermal withdrawal latency detection was 30 s. Mean ± SEM. n = 10; **p < 0.01 compared with the control group; ## p < 0.01 compared with the DM group for each group) (Fig. 2b) . These results revealed that sinomenine treatment may decrease the expression of DRG P2X 3 protein in T2DM rats.
Effects of sinomenine on the expression levels of DRG P38MAPK and p-P38MAPK in T2DM rats
Phosphorylation and activation of P38MAPK are involved in inflammatory pain. The expression levels of P38MAPK and p-P38MAPK in DRG were analyzed using western blotting. The integrated optical density (IOD) ratio of P38MAPK to β-actin was not significantly different between the two groups (p > 0.05). However, the IOD ratio of p-P38MAPK to P38MAPK in the T2DM group was higher than that of the control group (n = 10). These results indicated phosphorylation of P38MAPK in DRG is correlated with hyperalgesia mediated by the P2X 3 receptor in T2DM rats.
In addition, we examined whether the administration of sinomenine could affect the phosphorylation of P38MAPK in T2DM DRG. The IOD ratio of p-P38MAPK to P38MAPK in the T2DM rats treated with sinomenine was reduced by 5% compared with that in the T2DM group (p < 0.05, n = 10 for each group) (Fig. 3) . Taken together, these results suggest that the effects of sinomenine treatment on hyperalgesia mediated by the P2X 3 receptor may contribute to decreasing the phosphorylation and activation of P38MAPK in DRG in T2DM rats.
Effects of sinomenine on the ATP-activated currents in HEK293 cells transfected with the pEGFP-hP2X 3 plasmid
ATP-activated currents (I ATP ) in HEK293 cells transfected with the pEGFP-hP2X 3 plasmid were recorded by whole cell patch clamp. Sinomenine (10 μM) significantly inhibited about 5% ATP-activated (100 μM) current (Fig. 4) . We also observed that the specific selective P2X 3 antagonist A317491 (10 μM) can inhibit the transient ATP current. These results revealed that sinomenine treatment could relieve pain behaviors in T2DM rats by inhibiting the P2X 3 signaling in DRG.
Molecular docking of sinomenine on a hP2X 3 receptor
Molecular docking of sinomenine on a hP2X 3 protein were generated by the AutoDock 4.2. Docking score of hP2X 3 and sinomenine (kcal/mol) showed that sinomenine was enabled the perfect fit to interact with hP2X 3 receptor (see Table 1 ). The perfect match enabled the sinomenine to interact with residues both deep in the ATP-binding pocket and in the outer sphere (Fig. 5) .
Discussion
Up to 50% of people with diabetes are attacked by peripheral neuropathies [5, 6, [10] [11] [12] . DPN in T2DM patients constitutes Fig. 2 Effects of sinomenine on the expression levels of DRG P2X 3 mRNA and protein in T2DM rats. a The expression levels of DRG P2X 3 mRNAwere examined using real-time RT-PCR. The relative values of P2X 3 mRNA expression in the T2DM group were higher compared with those in the control group (p < 0.01, n = 10 for each group). The relative values of P2X 3 mRNA expression in T2DM rats treated with sinomenine were significantly decreased compared with the DM group (p < 0.01, n = 10 for each group). Mean ± SEM, n = 10. **p < 0.01 compared with the control group; ## p < 0.01 compared with the DM group. b The expression levels of P2X 3 protein in DRG were examined using western blotting analyses. Image analysis revealed that the intensity values (integrated optical density, IOD) of P2X 3 protein expression (normalized to each β-actin internal control) in the DM group were higher compared with those in the control group. The intensity values of P2X 3 protein expression in T2DM rats treated with sinomenine were significantly lower compared with those in the DM group. Mean ± SEM, n = 10. ** p < 0.01 compared with the control group; ## p < 0.01 compared with the DM group a major risk factor for foot ulceration and amputation [6, [8] [9] [10] [11] [12] . Our results indicated that the threshold values of mechanical and thermal pain sensitivity in T2DM rat models were decreased compared with those in the control rats. Thermal and mechanical abnormal hyperalgesia in T2DM rats can be increased after lesion in diabetic peripheral neuropathy Fig. 3 Effects of sinomenine on the expression levels of DRG P38MAPK and p-P38MAPK in T2DM rats. The expression levels of P38MAPK and p-P38MAPK in DRG were analyzed using western blotting analyses. The IOD ratio of P38MAPK to β-actin was not significantly different between the two groups (p > 0.05). The IOD ratio of p-P38MAPK to P38MAPK in the T2DM group was higher compared with that in the control group (n = 10). The IOD ratio of p-P38MAPK to P38MAPK in the T2DM rats treated with sinomenine was significantly lower compared with that in the T2DM group (p < 0.01, n = 10 for each group). Mean ± SEM, n = 10. **p < 0.01 compared with the control group; ## p < 0.01 compared with the DM group [21] [22] [23] . However, there are no specific relief medications for DNP, and current therapies are often associated with serious side effects [6, 10, 12, 40] . Our experiments showed that the MWT and TWL in T2DM rats treated with sinomenine were significantly enhanced compared with rats in the T2DM model group. Thus, we speculated that sinomenine treatment could reduce mechanical and thermal hyperalgesia in T2DM rats. What mechanism contributed to the inhibitory effects of sinomenine treatment on mechanical and thermal hyperalgesia in T2DM rats? DM is often related to low-grade inflammation [6, 12] . ATP acts as an inflammatory mediator to participate in inflammatory-mediated pain [13-15, 17, 20, 41] . Damage to the peripheral nerve in neuropathic pain enhances the expression of the P2X 3 receptor in the DRG neurons and is involved in pain transmission [13] [14] [15] [16] [17] [18] 20] . Our results showed that the expression levels of P2X 3 mRNA and protein in DM DRG are enhanced compared with those in the control. P2X 3 receptormediated hyperalgesia is present in diabetic rat models [21] [22] [23] . Thus, the enhanced expression of the P2X 3 receptor in DRG may be accompanied with mechanical and thermal hyperalgesia in T2DM rats. Our data also showed that upregulated expression levels of the DRG P2X 3 mRNA and protein in DM rats treated with sinomenine were significantly decreased compared with those in T2DM rats. Sinomenine treatment may decrease the up-regulated expression of the P2X 3 receptor in T2DM DRG and relieve the mechanical and thermal hyperalgesia in T2DM rats. P2X 3 receptors are present mainly in small-to mediumsized neurons in the DRG. Selective distribution in small primary afferent neurons suggests a contributing role of the P2X 3 receptor in nociception and pain [42] . Activation of the P2X 3 receptor contributes to pain and hyperalgesia [43] . This study showed that the up-regulated expression of the P2X 3 receptor was followed by an enhancement of mechanical and thermal hyperalgesia, resulting in the subsequent activation of the P2X 3 receptor in the T2DM DRG. Cytokines liberated in the setting of peripheral inflammation contribute to pain. Thus, NONRATT021972 siRNA treatment could reduce the serum levels of TNF-α in T2DM rats, decrease the up-regulated expression of the P2X 3 receptor in DRG, and relieve P2X 3 receptor-mediated DNP in T2DM rats. This finding further confirmed that NONRATT021972 might be involved in the pathological process of T2DM.
To identify whether sinomenine could specifically inhibit signal transduction through the P2X 3 receptor, a model of P2X 3 receptor expression was established in HEK293 cells. HEK293 cells do not natively express any known P2X 3 or other receptors; when unmodified HEK293 cells do not respond to P2X 3 agonist stimulation. To validate this work, constructs expressing human P2X 3 plasmid were transiently transfected into HEK293 cells as previously described [34, 35] . Our data showed that sinomenine significantly inhibited P2X 3 agonist ATP-activated currents in the transfected HEK293 cells. The P2X 3 -specific antagonist, A317491, can inhibit the ATP-activated currents in the transfected HEK293 cells. The inhibition effect of sinomenine was similar to that of A317491, which suggested that a specific inhibitory effect of sinomenine on P2X 3 may be a competitive blockade. These results confirmed that sinomenine inhibited mechanical and heat hyperalgesia mediated by the P2X 3 receptor in T2DM rats. The electrophysiological results were consistent with down-regulation of P2X 3 expression after sinomenine treatment, which relieved the mechanical and heat hyperalgesia in T2DM rats. As shown in Fig. 5 , sinomenine could interact with the hP2X 3 . Interaction energies for the dockedcomplexes were calculated by AutoDock 4 and shown in Table 1 . In Table 1 , a higher value of negative interaction energy is an indicator of more efficient interaction between the hP2X 3 and sinomenine. Sinomenine could bind to the hP2X 3 to limit the combination of ATP, increasing the concentration of free ATP, leading to inhibition of the hP2X 3 channel. Therefore, sinomenine may act as the inhibitor of P2X 3 receptor.
P38 is activated in DRG nociceptor neurons by peripheral inflammation and participates in the generation 3 . The docking position was in the outside of the cell membrane and the entrance of the channel. c The docking pocket; the blue surface and stick-like structure were the B chain of the hP2X 3 protein and the orange surface and stick-like structure and the place covered by the blue surface were the C chain of the hP2X 3 protein. The yellow dotted line was a hydrogen bond between the residues on the chains and sinomenine. The photo indicated that there was a strong binding energy between sinomenine and GLN95 in the B chain and ALA94 and GLN95 in the C chain. The results revealed that sinomenine could interact with the hP2X 3 protein and maintenance of inflammatory and neuropathic pain [44, 45] . Therefore, blockade of P38MAPK activation in DRG is likely able to decrease mechanical and heat hypersensitivity in inflammatory and neuropathic pain. The activation of the P2X 3 receptor increases primary afferent nociceptor susceptibility to the action of inflammatory mediators [41] . The phosphorylated P38 levels are in response to inflammatory stimuli or nerve injury [44, 45] . ATP induced activation of P38 [41] . Activation of the P2X 3 receptor may be related to the phosphorylation of P38MAPK in DRG, causing mechanical and heat hyperalgesia of the nerve injury. Our studies showed that the IOD ratio of p-P38MAPK to P38MAPK in the T2DM group was higher compared with that of the control group. P38MAPK phosphorylation in DRG may be involved in mechanical and heat hyperalgesia mediated by the P2X 3 receptor in T2DM rats. After the administration of sinomenine, the IOD ratio of p-P38MAPK to P38MAPK in T2DM rats was significantly decreased compared with that in the T2DM rats that did not receive sinomenine. Sinomenine inhibited the phosphorylation of p38MAPK in the inflammatory condition [46] . Sinomenine treatment may decrease the phosphorylation and activation of DRG P38MAPK in T2DM rats and relieve mechanical and heat hyperalgesia mediated by the P2X 3 receptor.
Conclusions
In summary, sinomenine treatment reduced the up-regulated expression and activation of the P2X 3 receptor and decreased the phosphorylation and activation of P38MAPK in T2DM DRG, subsequently relieving thermal and mechanical hyperalgesia in T2DM rats. Thus, sinomenine treatment may alleviate DNP by inhibiting the abnormal excitatory transmission mediated by the P2X 3 receptor in T2DM rats.
